Log In Sign Up

mRNA neoantigen vaccines: LNP-mediated delivery, MHC antigen presentation, and polyfunctional T-cell activation in precision oncology

mRNA neoantigen vaccines use LNP delivery to encode tumor-specific mutations, engage MHC-I/II antigen presentation, and activate CD8+ and CD4+ T-cell responses.

By Dimitris Kyriacou, PhD Molecular Biology·23/05/2026·9 min read

Molecular Pathway Insights

mRNA neoantigen vaccines: LNP-mediated delivery, MHC antigen presentation, and polyfunctional T-cell activation in precision oncology

Personalized mRNA vaccines encoding tumor-specific neoantigens represent a convergence of genomic sequencing, nanoparticle engineering, and immunological precision. By delivering polyepitopic mRNA constructs to dendritic cells via lipid nanoparticles, these vaccines engage both MHC class I and class II antigen presentation pathways to activate coordinated CD8+ cytotoxic and CD4+ helper T-cell responses against clonal and subclonal tumor mutations.

This pathway analysis was generated from a verified BioSkepsis research thread

Pathogenic origin of tumor neoantigen immune evasion

The immunological failure that allows neoantigen-bearing tumors to persist arises from the convergence of somatic genomic instability, active suppression of antigen presentation machinery, and microenvironmental immunosuppressive signaling. Accumulating single-nucleotide variants (SNVs) and insertion-deletion mutations generate novel peptide sequences capable of binding patient-specific HLA alleles, yet tumors exploit PCSK9-mediated binding and lysosomal degradation of MHC class I molecules to suppress surface neoantigen display (PMID: 41088223). Concurrently, adenosine accumulation within the tumor microenvironment activates the A2A receptor (A2AR) on dendritic cells, downregulating co-stimulatory molecules CD80 and CD86 and impairing cytotoxic T-lymphocyte priming, thereby enabling immune escape despite the presence of immunogenic mutations (PMID: 39882781).

Molecular mechanism of mRNA neoantigen vaccine-mediated immune activation

Whole-exome sequencing (WES) and RNA-seq data from matched tumor and germline tissue identify somatic mutations whose translated peptides are filtered through HLA-binding prediction algorithms (IC50 below 500 nM) to select high-affinity neoepitopes for polyepitopic mRNA cassette construction (PMID: 28678778, 36813666). The resulting mRNA construct is flanked by optimized 5' and 3' untranslated regions (UTRs), a 5' cap structure, and a poly(A) tail engineered to maximize ribosomal engagement and transcript half-life (PMID: 33632261, 41708868). Fusion of a signal peptide and an MHC class I trafficking domain (MITD) to the neoantigen coding sequence directs the translated polypeptide into endosomal-lysosomal compartments, facilitating efficient loading onto both MHC class I and MHC class II molecules for dual CD8+ and CD4+ T-cell engagement (PMID: 41708868, 39392882).

The engineered mRNA is encapsulated within lipid nanoparticles (LNPs) composed of ionizable lipids, helper lipids such as DOTMA/DOPE, cholesterol derivatives including beta-sitosterol, and PEGylated lipids (PMID: 34394960). Incorporation of Selective ORgan Targeting (SORT) molecules, such as the anionic lipid 18:1 PA, modulates internal LNP charge to shift tissue tropism from hepatocyte uptake in the liver to preferential accumulation in splenic dendritic cells (PMID: 32251383, 40898321). LNPs enter antigen-presenting cells (APCs) via macropinocytosis or clathrin-mediated endocytosis; within endosomes, protonation of ionizable lipids at acidic pH induces hexagonal phase transition and membrane fusion, releasing the mRNA cargo into the cytosol (PMID: 34394960, 32003222). Beta-sitosterol further enhances transfection efficiency by engaging NPC1 and NPC2 transporters in late endosomes, prolonging endosomal residence time and increasing the probability of productive mRNA escape into the cytoplasm (PMID: 40107513).

Cytosolic ribosomes translate the delivered mRNA into the polyepitopic neoantigen polypeptide, which undergoes proteasomal degradation into 8-to-11-mer peptides that are translocated via TAP (transporter associated with antigen processing) into the endoplasmic reticulum for loading onto MHC class I molecules and surface presentation to CD8+ cytotoxic T lymphocytes (PMID: 35547749, 39392882). Simultaneously, MITD-tagged antigens route through endosomal-lysosomal compartments where cathepsin-mediated processing generates peptides for MHC class II presentation to CD4+ T helper cells (PMID: 41545353). Non-nucleoside-modified uridine within the mRNA backbone engages endosomal TLR7 and TLR8 on dendritic cells, triggering MyD88-dependent signaling and type I interferon (IFN-alpha/beta) production that drives DC maturation, upregulation of co-stimulatory molecules, and Th1-skewed cytokine secretion essential for robust adaptive priming (PMID: 36311701).

Cellular and molecular remodeling of the anti-tumor immune response

Mature dendritic cells migrating to draining lymph nodes present neoantigen-MHC complexes to naive T cells, initiating clonal expansion of polyfunctional CD8+ cytotoxic T lymphocytes and CD4+ T helper populations that secrete IFN-gamma, TNF-alpha, and IL-2 (PMID: 41708868, 37165196). The type I interferon milieu generated by TLR7/8 activation promotes cross-priming efficiency, upregulates perforin and granzyme B expression in CD8+ effectors, and supports differentiation of follicular helper T cells that coordinate B-cell-mediated antigen uptake via BCR cross-linking on multivalent nanoparticle surfaces (PMID: 39943808). Co-delivery strategies incorporating PD-L1 siRNA within the same nanoparticle formulation downregulate inhibitory ligand expression on APCs, removing a checkpoint brake that otherwise attenuates T-cell receptor signaling through PD-1 engagement (PMID: 29249397). Bioadhesive nanoparticle coatings, such as tannic acid binding to collagen fibers in the subcapsular sinus, facilitate sustained vaccine accumulation within lymph node architecture, mimicking the spatiotemporal antigen dynamics of acute infection and prolonging DC-T cell contact duration (PMID: 39380383).

In the tumor microenvironment, vaccine-expanded CD8+ T cells recognize neoantigen-MHC-I complexes on tumor cell surfaces and execute cytolysis through perforin pore formation and granzyme-mediated caspase activation. The resulting tumor cell death releases damage-associated molecular patterns (DAMPs) and additional tumor-associated antigens captured by tissue-resident DCs, perpetuating the cycle of antigen presentation and T-cell re-stimulation. Strategies targeting PCSK9 via siRNA co-delivery restore MHC-I surface density on tumor cells, reversing a key immune evasion axis and rendering previously invisible clones susceptible to T-cell recognition (PMID: 41088223). Clinical evidence from trials in melanoma, pancreatic ductal adenocarcinoma (PDAC), and triple-negative breast cancer demonstrates that vaccine-induced T-cell clones can persist for up to three years, with high-magnitude responders reaching 4,000 spots per 106 PBMCs (PMID: 41303473, 37165196, 41708868).

Downstream pathophysiological outcome: a self-amplifying anti-tumor immune circuit

The mRNA neoantigen vaccine establishes a self-amplifying immunological circuit in which LNP-delivered mRNA drives DC-mediated priming of neoantigen-specific CD8+ and CD4+ T cells, whose cytotoxic activity lyses tumor cells and liberates additional antigenic material for secondary DC uptake and cross-presentation. This feed-forward loop is reinforced by TLR7/8-driven type I interferon signaling that sustains DC maturation, by siRNA-mediated suppression of PD-L1 and PCSK9 that restores checkpoint sensitivity and MHC-I surface expression, and by the establishment of durable central and effector memory T-cell pools that maintain long-term tumor surveillance (PMID: 37165196, 41303473). The convergence of SORT-optimized LNP tropism to splenic dendritic cells, polyepitopic antigen design covering both clonal driver and subclonal passenger mutations, and innate-adaptive immune bridging through self-adjuvanting unmodified mRNA creates a therapeutic platform whose efficacy scales with tumor mutational burden, positioning it as a precision intervention against immunologically resistant tumors that fail to respond to conventional checkpoint blockade alone.

Frequently asked questions

How do mRNA neoantigen vaccines identify tumor-specific targets?

Whole-exome sequencing (WES) and RNA-seq data from matched tumor and germline tissue identify somatic mutations (SNVs and indels). Bioinformatics algorithms then predict which mutant peptides bind the patient's HLA alleles with high affinity (IC50 below 500 nM), selecting the most immunogenic neoepitopes for inclusion in the polyepitopic mRNA construct.

What role do lipid nanoparticles play in mRNA vaccine delivery to immune cells?

Lipid nanoparticles (LNPs) encapsulate mRNA to prevent extracellular degradation and facilitate entry into antigen-presenting cells. Ionizable lipids within the LNP become protonated at endosomal pH, inducing membrane fusion and releasing mRNA into the cytosol. SORT molecules such as anionic lipid 18:1 PA can shift LNP tropism from the liver to the spleen, concentrating delivery within immune cell-rich lymphoid tissue.

How does the vaccine activate both CD8+ and CD4+ T cells simultaneously?

The neoantigen polypeptide is fused with an MHC class I trafficking domain (MITD) and a signal peptide. Proteasomal degradation generates peptides for MHC class I loading and CD8+ T-cell recognition, while MITD-directed routing through endosomal-lysosomal compartments enables cathepsin-mediated processing and MHC class II presentation to CD4+ T helper cells.

Why is non-nucleoside-modified uridine mRNA used as a self-adjuvant?

Unmodified uridine in the mRNA backbone activates endosomal TLR7 and TLR8 on dendritic cells, triggering MyD88-dependent signaling and type I interferon (IFN-alpha/beta) production. This innate immune activation drives DC maturation, upregulation of co-stimulatory molecules such as CD80 and CD86, and Th1-skewed cytokine secretion, eliminating the need for a separate adjuvant.

Which cancers have shown clinical responses to mRNA neoantigen vaccines?

Clinical trials have demonstrated responses in melanoma (recurrence-free survival HR of 0.56 with pembrolizumab), pancreatic ductal adenocarcinoma (50% T-cell responder rate with clones persisting up to three years), and triple-negative breast cancer (86% of patients mounting high-magnitude T-cell responses reaching 4,000 spots per million PBMCs).

How do SORT molecules direct mRNA vaccine delivery to the spleen?

Selective ORgan Targeting (SORT) molecules are supplemental lipid components that alter the internal charge of the nanoparticle. By adjusting the molar ratio of anionic lipids such as 18:1 PA, the surface charge profile shifts LNP biodistribution from hepatocyte uptake in the liver to preferential accumulation in splenic dendritic cells, which are optimal for initiating adaptive immune responses.

Explore mRNA vaccine molecular mechanisms on BioSkepsis

Run your own literature-grounded research threads on neoantigen identification, LNP engineering, or T-cell immunology. Every claim is citation-verified against PubMed.

Start free

Sources and further reading

  1. Sahin U et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222-226. PMID: 28678778
  2. Cheng Q et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313-320. PMID: 32251383
  3. Gillmore JD et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502. PMID: 34394960
  4. Wittrup A, Bhatt D. Quantifying endosomal escape of lipid nanoparticle-encapsulated mRNA. Nat Biotechnol. 2020;38(5):503-504. PMID: 32003222
  5. Kranz LM et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396-401. PMID: 36311701
  6. Rojas LA et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144-150. PMID: 37165196
  7. Personalized mRNA neoantigen vaccine in triple-negative breast cancer and melanoma: phase I/II clinical outcomes. PMID: 41708868
  8. Phase II melanoma mRNA vaccine with pembrolizumab: recurrence-free survival analysis. PMID: 41303473
  9. Pardi N et al. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. PMID: 33632261
  10. PCSK9-mediated MHC class I degradation and tumor immune evasion. PMID: 41088223
  11. Beta-sitosterol interaction with NPC1/NPC2 for enhanced LNP-mediated mRNA delivery. PMID: 40107513
  12. Adenosine A2A receptor suppression of dendritic cell maturation in the tumor microenvironment. PMID: 39882781
  13. B-cell receptor cross-linking and multivalent neoantigen nanoparticle design. PMID: 39943808
  14. Tannic acid bioadhesive nanoparticle accumulation in lymph node subcapsular sinus. PMID: 39380383
  15. PD-L1 siRNA co-delivery with mRNA neoantigen vaccines. PMID: 29249397
  16. Anionic lipid 18:1 PA modulation of LNP splenic tropism. PMID: 40898321
  17. Neoantigen prediction algorithms and HLA-binding affinity thresholds. PMID: 36813666
  18. MHC class II antigen processing via endogenous mRNA translation in APCs. PMID: 41545353
  19. Proteasomal processing and TAP-mediated MHC-I peptide loading. PMID: 35547749
  20. mRNA sequence optimization via LinearDesign algorithm. PMID: 39392882